MAIA Biotechnology is a clinical-stage biopharmaceutical company developing cancer therapies that target telomeres through immunotherapy.
MAIA Biotechnology has raised $30.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
MAIA Biotechnology's investors include National Institutes of Health, Checkmate Capital, KIZOO Technology Capital, MDL Investments, Benjamin Kong.
MAIA Biotechnology is headquartered in Chicago, United States.
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing cancer therapies that target telomeres through immunotherapy.
MAIA Biotechnology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MAIA Biotechnology — Funding & Investors." VCBacked, March 2, 2026, https://www.vcbacked.co/company/maia-biotechnology. Accessed August 14, 2026.
VCBacked. (2026). MAIA Biotechnology — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/maia-biotechnology
{{cite web |title=MAIA Biotechnology — Funding & Investors |url=https://www.vcbacked.co/company/maia-biotechnology |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated